Standout Papers

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced ... 2019 2026 2021 2023 255
  1. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial (2019)
    Yi‐Long Wu, Shun Lü et al. Journal of Thoracic Oncology

Immediate Impact

3 from Science/Nature 56 standout
Sub-graph 1 of 22

Citing Papers

Artificial intelligence in drug development
2025 Standout
Artificial intelligence in vaccine research and development: an umbrella review
2025 Standout
1 intermediate paper

Works of Junliang Cai being referenced

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
2019 Standout

Author Peers

Author Last Decade Papers Cites
Junliang Cai 387 441 51 60 12 516
John A. Kosteva 194 406 47 71 11 459
Catherine Wadsworth 406 426 50 72 17 540
Shawn Kothari 172 398 37 93 12 514
Balazs Medgyasszay 417 566 48 88 7 612
Munehiro Ito 312 476 54 79 13 533
J-L. Pujol 454 409 63 46 15 643
Maria Bassanelli 320 409 38 54 23 534
Mahmoud Ould-Kaci 244 423 53 66 17 533
Armando Preatoni 478 379 34 37 10 591
Audrey Simonaggio 265 426 46 77 23 537

All Works

Loading papers...

Rankless by CCL
2026